BioAge’s NLRP3 inhibitor shows potential to reduce cardiovascular risk
BioAge will be initiating a Phase IIa trial of the candidate in H1 2026.
Therapy Area
Ollin Biosciences’ OLN324 bests Vabysmo in DME and wAMD head-to-head trial
Pulmocide stops IPA trial after higher mortality rate in treated patients
GSK to file for approval of hep B drug on positive Phase III data
Arrowhead’s RNAi-based obesity drug combo shows benefit in Phase I/IIa trial
Neumora’s Alzheimer’s disease agitation drug shows early success in Phase Ib trial
MetaVia OXM analogue agonist meets endpoints in Phase Ib weight loss trial
Genmab shelves Phase III lung cancer candidate
